Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | DPYD | Q12882 | 4/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | THPO | P40225 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | HBB | P68871 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Uracil SCHEMBL27791187 | 0.86 | CRBN (0.57) | ATAD2LMNAMEN1KMT2APOLB | |
| SCHEMBL29360767 | 0.78 | MEN1 (0.33) | ATAD2LMNAMEN1KMT2APOLB | |
| SCHEMBL28955974 | 0.77 | ATAD2 (0.47) | ATAD2LMNAMEN1KMT2APOLB | |
| SCHEMBL21184262 | 0.77 | MAPT (0.54) | ATAD2LMNAMEN1KMT2APOLB | |
| SCHEMBL30271087 | 0.75 | MEN1 (0.49) | ATAD2LMNAMEN1KMT2APOLB | |
| SCHEMBL190171 | 0.75 | LMNA (0.49) | ATAD2LMNAMEN1KMT2APOLB | |
| SCHEMBL20534511 | 0.75 | LMNA (0.62) | LMNAMEN1KMT2APOLBMAPT | |
| SCHEMBL1518339 | 0.72 | MAPT (0.50) | ATAD2LMNAMEN1KMT2APOLB | |
| SCHEMBL84844 | 0.71 | — | — | |
| Thymine SCHEMBL27966424 | 0.71 | ATAD2 (0.83) | ATAD2LMNAMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120153078-A | RNA molecules encoding RSV-F and vaccines containing the same | 辉瑞大药厂 | 2025-06-13 | — | — | CN | disclosed |
| US-20250154157-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | CANCER RESEARCH TECH LTD (GB) | 2025-05-15 | — | — | US | disclosed |
| EP-4479400-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | Cancer Research Technology Limited (GB) | 2024-12-25 | — | — | EP | disclosed |
| CN-119053604-A | Heterocyclic compounds for the treatment of ERK5 mediated diseases | 癌症研究技术有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-20240124460-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2024-04-18 | — | — | US | disclosed |
| WO-2023205465-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023156791-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-08-24 | — | — | WO | disclosed |
| WO-2023156791-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2023-08-24 | — | — | WO | disclosed |
| EP-4229061-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | Ranok Therapeutics (Hangzhou) Co. Ltd. (CN) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022078350-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| WO-2022078350-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | RANOK THERAPEUTICS (HANGZHOU) CO. LTD. (CN) | 2022-04-21 | — | — | WO | disclosed |
| US-10793542-B2 | Hetroarylamine compounds for modulating the hedgehog pathway and preparing method and uses thereof | DEVELOPMENT CENTER FOR BIOTECHNOLOGY (TW) | 2020-10-06 | — | — | US | disclosed |
| CN-111373057-A | Methods and compositions for screening and identifying splice modulators | 斯基霍克疗法公司 | 2020-07-03 | — | — | CN | disclosed |
| CN-111132552-A | Compositions and related methods for modulating endosymbionts | 旗舰创业创新五公司 | 2020-05-08 | — | — | CN | disclosed |
| WO-2009120493-A2 | STABILIZED COMPOSITIONS OF ALKYLATING AGENTS AND METHODS OF USING SAME | YAUPON THERAPEUTICS, INC (US) | 2009-10-01 | — | — | WO | disclosed |
| US-3935184-A | Synthetic polyoxin type nucleosides | SYNTEX (U.S.A.) INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10793542-B2 | Hetroarylamine compounds for modulating the hedgehog pathway and preparing method and uses thereof | SHH, GLI1, NR1H4 | ATAD2 2673/4885LMNA 3757/4885MEN1 1588/4885 |
| US-20240124460-A1 | METHODS AND COMPOSITIONS FOR TARGETED PROTEIN DEGRADATION | PSMG3, PSMC2, PSMA6 | ATAD2 2548/4885LMNA 1362/4885MEN1 1454/4885 |
| US-20250154157-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR TREATING A ERK5-MEDIATED DISEASE | MAP3K5, MAPK1, MAP3K20 | ATAD2 4672/4885LMNA 2790/4885MEN1 896/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.